Oasis Discussions

Dealing with systemic diseases in the elderly patient

This summary is based on the article published in Dental Clinics of North America: Systemic Diseases and Oral Health (October 2014)

Mary Tavares, DMD, MPH; Kari A. Lindefjeld Calabi, DMD; Laura San Martin, DDS, PhD, MDPH

 

 

 

 

 

Context

Scope of the Article

The authors have chosen to select cardiovascular diseases (CADs), hypertension, diabetes, arthritis, osteoporosis, and stroke to discuss in this article.

Their connection to oral health is highlighted and oral recommendations are provided. 

Key Messages

Diabetes Mellitus

DM is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.

Oral Health Implications of Diabetes

Drug Interactions and Effects

Recommendations for Providing Dental Care to Diabetics

Hypertension

Hypertension is defined as systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg. It is one of the most common and potentially dangerous medical conditions among the elderly, affecting approximately two-thirds of men and three-quarters of women 75 years and older.7-8

Oral Health Implications of Hypertension

Drug Interactions and Effects

Recommendations for Providing Dental Care 

Cardiovascular Diseases (CVDs)

CVD refers to any disease that affects the heart, the blood vessels (arteries, capillaries, and veins), or both.

Oral Health Implications of Hypertension

No oral manifestations are related to CVDs per se; however, side effects of medications used to treat CVDs affect the oral cavity. Dry mouth, burning of the mouth, taste changes, and lichenoid reactions are linked to side effects of heart failure medications.19

Drug Interactions and Effects

Recommendations for Providing Dental Care 

Cerebrovascular disease

Stroke is a cerebrovascular disorder characterized by a sudden interruption of blood flow to the brain, causing oxygen deprivation. It is frequently seen in patients with current CVDs.60 Stroke is the fourth leading cause of death in the United States and a major cause of adult disability.22-23

Oral Health Complications of Stroke

Stroke patients are very vulnerable to oral diseases because of the limitations in the activities of daily living and impaired manual dexterity.24

Inadequate oral hygiene combined with xerostomia leads to additional oral problems, such as candidiasis, dental caries, periodontitis, mucosal lesions, and tooth loss.

Drug Interactions and Effects

These drug interactions and effects are similar to those discussed in the CVDs section.

Recommendations for Providing Dental Care  

Arthritis

Arthritis is a musculoskeletal disorder characterized by the inflammation of one or more joints, causing pain and stiffness in the affected joints.26

Oral Health Implications of Arthritis

Drug Interactions and Effects

Recommendations for Providing Dental Care to Patients with Arthritis

Osteoporosis

Osteoporosis is defined as a skeletal disorder that compromises bone strength, predisposing a person to an increased risk of bone fracture due to inhibited calcium intake and mineral loss.

Oral Health Implications of Osteoporosis

Studies have shown that mandibular and maxillary bone densities, as well as alveolar BMD and height, are modestly correlated with other skeletal sites. However, whether low BMD in the jaw results in other adverse changes, such as missing teeth, gingival bleeding, greater probing depth, and gingival recession, is still unclear.30

Drug Interactions and Effects

Bisphosphonates: Patients treated with IV bisphosphonates have a risk of developing bisphosphonates-related osteonecrosis of the jaw (BRONJ). This risk increases when the duration of the therapy exceeds 3 years.31 Patients taking oral bisphosphonates are at a considerably lower risk.32

Recommendations for Providing Dental Care to Patients with Osteoporosis

Dentists should be aware of the implications and possible risks when patients are under bisphosphonates therapy.33

Oral bisphosphonate therapy, Beginning IV bisphosphonate therapy, IV bisphosphonate therapy for <3 mo with no osteonecrosis of the jaw

IV bisphosphonate therapy for 3 mo or more with no osteonecrosis of the jaw

Bisphosphonate therapy with osteonecrosis of the jaw

 

References

  1. O. Freire, T.E. Van Dyke. The oral-systemic health connection. A guide to patient care. M. Glick (Ed.), Chapter 5: the mechanisms behind oral-systemic interactions (1st edition), International Quintessence Publishing Group, Chicago (2014), pp. 103–117.
  2. Appendix C. Drug interactions of significance to dentistry. Table c-1 J.W. Little (Ed.), Dental management of the medically compromised patient (6th edition), Mosby, Missouri (2002), pp. 541–570.
  3. Insulin, oral hypoglycemics, and glucagon. Chapter 36 J.A. Yagiela (Ed.), Pharmacology and therapeutics for dentistry (5th edition), Mosby, Missouri (2004), pp. 573-582.
  4. de Jager, A. Kooy, P. Lehert, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomized placebo controlled trial. BMJ, 340 (2010), p. c2181
  5. A. Field, J.A. Speechley, F.R. Rugman, et al. Oral signs and symptoms in patients with undiagnosed vitamin B12 deficiency. J Oral Pathol Med, 24 (10) (1995), pp. 468-470.
  6. Box 31.14 Principles of dental management of diabetics R.A. Cawson (Ed.), Cawson’s essentials of oral pathology and oral medicine e-book (8th edition), Churchill Livingstone, Edinburgh (2012) VitalBook file.
  7. Lipsitz LA. A 91-year-old woman with difficult-to-control hypertension. Aclinical review. JAMA 2013;310:1274–80. Available at: http://jama.jamanetwork.com.ezpprod1.
  8. Lloyd-Jones D, Adams R, Camethon M, et al, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics- 2009 update. Circulation 2009;119 (3):e21–181.
  9. Herman WW, Konzelman JL Jr, Prisant LM, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. New national guidelines on hypertension. A summary for dentistry. J Am Dent Assoc 2004; 135:576–84.
  10. Kerr AR, Phelan JA. Benign lesions of the oral cavity. Chapter 6. Drug-induced gingival enlargement. In: Greenberg MS, editor. Burket’s oral medicine. 11th Hamilton: B.C. Decker; 2007. p. 129–52.
  11. Dental Considerations for Geriatric Patients. CME resource. 2013. p. 8. Available at: http://www.netce.com/839/Course_3956.pdf.
  12. Dental Considerations for Geriatric Patients. CME resource. 2013. p. 7. Available at: http://www.netce.com/839/Course_3956.pdf.
  13. Becker DE. Cardiovascular drugs: implications for dental practice part 1-cardiotonics, diuretics and vasodilators. Anesth Prog 2007;54:178–86 DDS2007 by the American Dental Society of Anesthesiology. p. 180. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213250/.
  14. Texas Health and Human Services Commission. Criteria for outpatient Use Guidelines. Nonsteroidal Anti-Inflammatory Drugs. Available at: http://www.txvendordrug.com/downloads/criteria/nsaids.shtml.
  15. Little JW, Falace DA, Miller CS, et al. Hypertension. In: Dental management of the medically compromised patient. 7th edition. Missouri: Mosby; 2008. p. 34–66.
  16. Dental Considerations for Geriatric Patients. CME resource. 2013. p. 6. Available at: http://www.netce.com/839/Course_3956.pdf.
  17. Becker DE. Cardiovascular drugs: implications for dental practice part 1-cardiotonics, diuretics and vasodilators. Anesth Prog 2007;54:178–86 DDS2007 by the American Dental Society of Anesthesiology. p. 181. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213250/?report5classic.
  18. Gangavati A, Hajjar I, Quach L, et al. Hypertension, orthostatic hypotension and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc 2011;59:383–9. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306056/.
  19. Little JW, Falace DA, Miller CS, et al. Heart failure. In: Dental management of the medically compromised patient. Table 6-1 drugs used in the treatment of patients with heart failure. 7th edition. Missouri: Mosby; 2008. p. 81–9.
  20. Little JW, Falace DA, Miller CS, et al. Heart failure. In: Dental management of the medically compromised patient. 7th edition. Missouri: Mosby; 2008. p. 81–9. Box 6–7.
  21. Oral health topics: ultrasonis devices and cardiac pacemarkers. American Dental Association. Available at: http://www.ada.org/4933.aspx?currentTab52.
  22. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013;127: e6–245. Available at: http://www.cdc.gov/Other/disclaimer.html.
  23. Kochanek KD, Xu JQ, Murphy SL, et al. Deaths: final data for 2009. Natl Vital Stat Rep 2011;60(3):1–116.
  24. Yoshida M, Murakami T, Yoshimura O, et al. The evaluation of oral health in stroke patients. Gerodontology
  25. Scully C, Ettinger The influence of systemic diseases on oral health care in older adults. J Am Dent Assoc 2007;138:7S–14S. Available at: http://jada.ada.org.
  26. Arthritis Foundation. Available at: http://www.arthritis.org/conditions-treatments/understanding-arthritis/.
  27. Little JW, Falace DA, Miller CS, et al. Arthritic Diseases. In: Dental management of the medically compromised patient. 6th edition. Missouri: Mosby; 2002. p. 478–500.
  28. Amrein PC, Ellman L, Harris WH. Aspirin-induced prolongation of bleeding time and perioperative blood loss. J Am Med Assoc 1981;245:1825–8.
  29. Ferraris VA, Swanson E. Aspirin usage and perioperative blood loss in patients undergoing unexpected operations. Surg Gynecol Obstet 1983;156:439–42.
  30. Lamster IB, Northridge ME. Improving oral health for the elderly. New York: Springer; 2008. p. 127–56.
  31. Ruggiero SL, et al. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonates-related osteonecrosis of the jaw- 2009 updated. Available at: http://www.aaoms.org/docs/position_papers/bronj_update.pdf.
  32. Migliorati CA. Bisphosphonate-associated osteoradionecrosis: position statement. J Am Dent Assoc 2005;136:12.
  33. Hupp JR. Dental management of osteoporosis. C.V. Mosby; 2006. Dental Clinical Advisor. VitalBook file.
  34. Woo SB, Hellstein JW, Kalmar JR. Systematyc review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753–61.

 

2 Comments

  1. David Tessier November 22, 2014

    A particularly long BUT thorough article from Oasis;one of the best that I can say I will put to use as reference at the office on Monday.
    This is what I like to refer to as a professional “Recipe”,that I always look forward to take “home” with after a great course/lecture.
    My only wish was,especially this week having had to extract an anterior tooth in a patient on blood thinners,is a suggested range of INR that we can follow.Again,with this weeks experience with an extraction(no complications post-op,by the way),brought got my attention that there is no consistency in practice for whether to cease blood thinners(AT ALL!),or as to when to cease(Day of,1 day before,3…?)

    Reply
    1. Sremac November 25, 2014

      Great article, as far as CVA’s are concerned, some neurologists recommend postponing elective treatment up to 6 months.

      Reply

Leave a Comment

Your email address will not be published. Required fields are marked *